Tapering Prozac (fluoxetine)
Join us for the next installment of Outro’s Tapering Series, featuring Dr. Mark Horowitz, Scientific Co-Founder of Outro Health, for an in-depth discussion on Prozac (fluoxetine)—one of the most widely prescribed SSRIs for depression and anxiety.
Although Prozac has a longer half-life compared to other antidepressants, it still presents significant tapering challenges—especially for patients who have been on the medication for many years. In this session, Dr. Horowitz will break down the neurobiology of fluoxetine tapering, the misconceptions around its "easier" discontinuation, and why a hyperbolic tapering approach is essential for minimizing withdrawal risk and optimizing patient outcomes.
Can’t make it live? Register anyway and we’ll send you the recording.
🧠 What You’ll Learn
Why Prozac’s long half-life doesn’t guarantee a smooth taper—and what patients actually experience
The science of fluoxetine withdrawal: receptor adaptation, neurochemical impacts, and symptom presentation
How hyperbolic tapering improves safety and reduces the likelihood of withdrawal or misdiagnosed relapse
Practical tapering strategies specific to fluoxetine’s pharmacokinetics
How Outro’s virtual clinic model provides structured, clinician-supported hyperbolic tapering for Prozac and other antidepressants
🎙️ Presenter
Dr. Mark Horowitz, MD, PhD
Dr. Horowitz is a clinical research fellow in psychiatry at University College London and the Scientific Co-Founder of Outro Health. He co-authored the Maudsley Deprescribing Guidelines and is internationally recognized for his research on antidepressant withdrawal and hyperbolic tapering protocols. His work has helped reshape national guidelines on how to safely reduce and discontinue psychiatric medications.
Emma Frati is a member of the Outro Health team with lived experience of polypharmacy during her time at Columbia University. She later earned a degree in Behavioral Neuroscience with a focus on statistics and business. Emma has worked in psychedelic and wearables research, co-authored a study on automated sleep scoring published in Sleep Journal, and previously consulted in the rare disease biotech space.
About Outro
Outro is a virtual care platform for safe, evidence-based antidepressant tapering. They are currently accepting patients in several US states. Learn more by visiting the Outro website at www.outro.com